Clinical Trial Update: A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety and preliminary efficacy of Actinium-225 DOTATATE in combination with tislelizumab as maintenance therapy for extensive-stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• [225Ac]Ac-DOTATATE (Actinium-225 DOTATATE)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: SCLC, Extensive Stage | Phase 1 | Status: RECRUITING